Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

674 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.
Bug G, Koschmieder S, Krauter J, Heuser M, Thol F, Wiebe S, Hofmann WK, Klein SA, Wegener G, Göhring G, Heit W, Hoelzer D, Ganser A, Ottmann OG. Bug G, et al. Among authors: hoelzer d. Ann Hematol. 2014 Feb;93(2):193-202. doi: 10.1007/s00277-013-1873-3. Epub 2013 Aug 27. Ann Hematol. 2014. PMID: 23978944 Clinical Trial.
Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML.
Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Ganser A, Heil G. Krauter J, et al. Among authors: hoelzer d. Br J Haematol. 1998 Oct;103(1):72-8. doi: 10.1046/j.1365-2141.1998.00926.x. Br J Haematol. 1998. PMID: 9792292 Free article.
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D. Ganser A, et al. Among authors: hoelzer d. Ann Hematol. 2000 Jan;79(1):30-5. doi: 10.1007/s002770050005. Ann Hematol. 2000. PMID: 10663618 Clinical Trial.
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A. Hofmann WK, et al. Among authors: hoelzer d. Ann Hematol. 2004 Aug;83(8):498-503. doi: 10.1007/s00277-004-0889-0. Epub 2004 May 20. Ann Hematol. 2004. PMID: 15156346 Clinical Trial.
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A. Thol F, et al. Among authors: hoelzer d. Blood. 2010 Jul 29;116(4):614-6. doi: 10.1182/blood-2010-03-272146. Epub 2010 Apr 26. Blood. 2010. PMID: 20421455 Free article.
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M. Thol F, et al. Among authors: hoelzer d. J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13. J Clin Oncol. 2011. PMID: 21670448 Clinical Trial.
674 results